Free Preview
Lead Advisor Manisha Samy sits down with the Senior Vice President of Corporate Strategy and Finance of Cellectis, Simon Harnest, to discuss the complexities of creating an allogeneic approach for developing CAR-T therapies, especially for solid tumors. Simon addresses why Cellectis is up for the challenge. He also addresses the discrepancy between current valuations of Cellectis and competitor, Moderna (MRNA) who happens to license from Cellectis.
